Mometasone, cutaneous

Generic name
Mometasone, cutaneous
Brand name
ATC Code
D07AC13
Compare …

Mometasone, cutaneous

Dosages
Side effects in children
Warnings & precautions in children
Contra-indications in children

Interactions
PK
Renal impairment
References

Pharmacokinetics in children

Possibly low absorption and a large first-pass effect.

dose recommendation of formulary compared to licensed use (on-label versus off-label)

No information is present at this moment.

Available formulations

No information is present at this moment.

Dosages

Atopic dermatitis
  • Cutaneous
    • 2 years up to 18 years
      [1] [2] [4] [10]

      • Apply once daily according to fingertip unit method <insert link to FTU page>

        • Maximum dose:
          > 2 yrs: 50 g/week;
          Adults: 100 g/week.
        • At the start of the treatment, twice daily application for a short period can be considered.
        • If there is an improvement, reduce to once daily on 2-4 days a week before discontinuing therapy.

         

         
Psoriasis
  • Cutaneous
    • 2 years up to 18 years
      [10]

      • Apply once a day to the affected skin area according to fingertip unit method <insert hyperlink>

Renal impaiment in children > 3 months

GFR ≥10 ml/min/1.73m2: Dose adjustment not required.

GFR <10 ml/min/1.73m2: A general recommendation on dose adjustment cannot be provided.

The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here

Side effects in children

Systemic: intracranial hypertension (bulging fontanelles, headaches and bilateral papilloedema) has been reported in children (SmPC)

The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here

Contra-indications

No information available on specific contra indications in children.

The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here

Warnings & precautions in children

Children have relatively large skin surface area and thin skins. In them, prolonged use on large areas can lead more quickly to systemic side effects, adrenal cortex suppression and also to growth hormone suppression; in the event of prolonged use on large areas, regular checks on height and weight and determination of plasma cortisol levels are recommended. Do not use occluded (under nappies) in children.

Interactions

The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here

CORTICOSTEROIDS, PLAIN

This pages provides a list of drugs from the same ATC class for comparison. This does not necessarily mean that these drugs are interchangeable.

Corticosteroids, weak (group I)
D07AA02
Corticosteroids, moderately potent (group II)
D07AB02
Corticosteroids, potent (group III)
D07AC01
D07AC03
D07AC17

References

  1. Krakowski AC, et al, Management of Atopic Dermatitis in the Pediatric Population, Pediatrics, 2008, Vol. 122 No. 4, 812-824
  2. CBO, Richtlijn Constitutioneel Eczeem, www.cbo.nl, March 2015
  3. NHG, Standaard constitutioneel exceem (M37), www.nhg.nl, augustus 2006
  4. Dirven-Meijer PC et al., NHG standaard Eczeem, Huisarts Wet, 2014, 57(5), 240-52
  5. Dermapharm AG, SmPC, Momecutan Fettcreme 1 mg/g Creme (88647.00.00), 04/17
  6. Uptodate: UpToDate®, Pediatric Drug information: Mometason topical Lexicomp® Topic 9782 Version 159.0, accessed 10/18
  7. Dermapharm AG, SmPC, Momecutan Salbe 1 mg/g Salbe (88648.00.00), 04/17
  8. Dermapharm AG, SmPC, Momecutan Lösung 1 mg/g Lösung zur Anwendung auf der Haut (88649.00.00), 04/17
  9. MSD SHARP & DOHME GMBH, SmPC, ECURAL ® 1 mg/g Fettcreme/Salbe/Lösung zur Anwendung auf der Haut (29379.00.00, 29379.00.01, 29379.00.02), 08/17
  10. Merck Sharp & Dohme B.V. , SmPC Elocon (RVG 14173) 22-06-2021, www.geneesmiddeleninformatiebank.nl

Changes

Therapeutic Drug Monitoring


Overdose